Recently, empagliflozin (EMPA), a selective inhibitor of the sodium glucose co‐transporter 2, which reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial,41, 42 has been found to improve myocardial strain, and reduces cardiac pro‐inflammatory cytokines via regulating NLRP3 and MyD88‐related pathways in nondiabetic mice treated with doxorubicin.43 This evidence concerns the gene SLC5A2 and heart failure.